中國醫藥(600056.SH)擬改聘立信為2019年年度審計機構
格隆匯11月20日丨中國醫藥(600056.SH)公佈,經公司第七屆董事會第31次會議審議並通過《關於變更會計師事務所的議案》,公司擬改聘立信會計師事務所(特殊普通合夥)(“立信”)為公司2019年年度審計機構,聘期一年。
2019年4月17日,公司召開2018年年度股東大會,審議並通過了《關於2019年續聘會計師事務所的議案》,續聘致同會計師事務所(特殊普通合夥)(“致同”)為公司2019年年度審計機構。鑑於致同會計師事務所(特殊普通合夥)與公司控股股東中國通用技術(集團)控股有限責任公司(“通用技術集團”)的服務年限到期,根據國務院國有資產監督管理委員會《中央企業財務決算報告管理辦法》和《關於加強中央企業財務決算審計工作的通知》規定,各中央企業應嚴格按照“統一組織、統一標準、統一管理”原則,由企業總部依照有關規定委託會計師事務所對企業及各級子企業的年度財務決算進行審計。據此,經通用技術集團統一要求,並結合公司經營管理及業務發展需要,經公司董事會審計委員會評議,董事會同意公司改聘立信會計師事務所(特殊普通合夥)為公司2019年年度審計機構,聘期一年。
公司就該事項已事先與致同進行了溝通,並取得了理解和支持。致同在受聘期間,秉承“獨立、客觀、公正”的原則,以其專業的服務和豐富的經驗,按時為公司出具了各項審計報告,保證了公司審計報告的真實、準確和完整。董事會對致同提供的審計服務表示感謝和敬意。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.